Mucosal Atomization Devices Market Report 2026

Mucosal Atomization Devices Market Overview

• Mucosal Atomization Devices market size has reached to $0.92 billion in 2025 • Expected to grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Growing Prevalence Of Allergic Rhinitis Fueling The Growth Of The Market Due To Increasing Allergy Incidence • Market Trend: Advancements In Mucosal Atomization Devices • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Mucosal Atomization Devices Market?

Mucosal atomization devices offer medication through the nostrils. It is known for providing dependable topical solution atomization across the nasal and oropharyngeal mucous membranes. The mucosal atomization devices are used to deliver atomized medication to the mucosal surfaces of the nasal, oral, and larynx, trachea, and lungs. The main types of mucosal atomization devices include nasal atomization devices, fibre-optic atomization devices, laryngotracheal atomization devices, and bottle atomizer devices. Nasal atomization devices offer a painless, safe approach to giving patients fast-acting drugs that quickly penetrate mucosal membranes and enter the bloodstream. The different mucosal atomization device technologies include gas propelled atomization devices and electrical atomization devices, which are used by end-users including hospitals, ambulatory surgical centers, and specialized clinics.

What Is The Mucosal Atomization Devices Market Growth Forecast?

The mucosal atomization devices market size is expected to see rapid growth in the next few years. It will grow to $1.52 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing demand for non-invasive drug administration, rising adoption in emergency and anesthesia care, expansion of home healthcare usage, growing focus on infection control, increasing development of portable medical delivery devices. Major trends in the forecast period include increasing adoption of needle-free drug delivery devices, rising demand for rapid-acting emergency medications, growing use of single-use atomization devices, expansion of portable atomization solutions, enhanced focus on patient comfort and safety.

Global Mucosal Atomization Devices Market Segmentation

1) By Type: Nasal Atomization Devices, Laryngo-Tracheal Atomization Devices 2) By Technology: Gas-Propelled Atomization Devices, Electrical Atomization Devices 3) By End User: Hospitals, Ambulatory Surgical Centers, Specialized Clinics Subsegments: 1) By Nasal Atomization Devices: Handheld Nasal Sprays, Mechanical Nasal Atomizers, Electric Nasal Atomizers 2) By Laryngo-Tracheal Atomization Devices: Jet Nebulizers, Ultrasonic Nebulizers, Portable Laryngo-Tracheal Atomizers

What Is The Driver Of The Mucosal Atomization Devices Market?

The rising prevalence of allergic rhinitis is expected to propel the growth of the mucosal atomization devices market going forward. Allergic rhinitis is an inflammatory condition of the nasal passages caused by an allergic response to airborne substances such as pollen, dust mites, or pet dander. The growing prevalence of allergic rhinitis is largely driven by increasing air pollution and environmental allergens, as urban and industrial development releases higher concentrations of particulate matter and pollutants that trigger and exacerbate allergic responses in susceptible individuals. The rising prevalence of allergic rhinitis increases the need for efficient nasal drug delivery systems that rapidly administer medications directly to affected nasal tissues, providing quick relief from symptoms such as congestion, sneezing, and inflammation. For instance, in January 2024, according to the UK Health Security Agency (UKHSA), a UK-based government agency, during week 23, consultations for allergic rhinitis rose sharply, reflecting current grass pollen levels and recent warm weather. The highest consultation rates were seen among individuals aged 5–14 and 15–44 years. Therefore, the rising prevalence of allergic rhinitis is driving the growth of the mucosal atomization devices industry.

Key Players In The Global Mucosal Atomization Devices Market

Major companies operating in the mucosal atomization devices market are Teleflex Incorporated, Cook Medical LLC, Pulmodyne Inc., Life-Assist Inc., Vyaire Medical Inc., Mercury Medical, SunMed LLC, Salter Labs, Armstrong Medical Industries Inc., VBM Medizintechnik GmbH, Intersurgical Ltd., Flexicare Medical Limited, Medovations Inc., Atom Medical Corporation, BLS Systems Limited, Dali Medical Devices Co. Ltd., Trudell Medical International, PARI GmbH, Omron Healthcare Inc., Drive Medical Holdings LLC, Laerdal Medical AS

Global Mucosal Atomization Devices Market Trends and Insights

Major companies operating in the mucosal atomization device market are focusing on developing technological advancement such as metal-free nasal spray pumps, to provide a better experience for patients. Metal-free nasal spray pumps refer to dispensing systems designed without any metallic components, ensuring that the nasal formulation comes into contact only with non-metallic materials such as plastics or polymers. For instance, in January 2023, Aptar Pharma, a US-based pharmaceutical company, launched the APF Futurity. The APF Futurity is a metal-free, multidose nasal spray pump created for delivering nasal saline and similar over-the-counter (OTC) formulations. It is Aptar Pharma's first highly recyclable nasal spray pump, having earned a Class AA certification from cyclos-HTP for recycling in Europe. Made from polyolefin materials without any metal components or recycling disruptors, APF Futurity minimizes separation efforts in recycling streams and promotes higher quality recyclates.

What Are Latest Mergers And Acquisitions In The Mucosal Atomization Devices Market?

In October 2024, Aptar Pharma Inc., a U.S.-based healthcare technology company, acquired all device technology assets of SipNose Nasal Delivery Systems Ltd. for an undisclosed amount. With this acquisition, Aptar Pharma aimed to strengthen its intranasal drug delivery portfolio, especially its nose-to-brain capabilities, by integrating SipNose’s advanced systems, accelerating the development of innovative therapies for central nervous system and systemic diseases, expanding its technological leadership in precision nasal delivery, and increasing its competitiveness in the global pharmaceutical delivery market. SipNose Nasal Delivery Systems Ltd. is an Israel based medical technology company that specializes in providing intranasal delivery platform.

Regional Outlook

North America was the largest region in the mucosal atomization devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Mucosal Atomization Devices Market?

The mucosal atomization devices market consists of sales of 3cc Syringe and VetJet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.